Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine

David W. Haas, Eduardo Arathoon, Melanie A. Thompson, Rogiero De Jesus Pedro, Joel E. Gallant, David E. Uip, Judith Currier, L. Miguel Noriega, David S. Lewi, Patricia Uribe, Jorge Benetucci, Pedro Cahn, David Paar, A. Clinton White, Ann C. Collier, Carlos H. Ramirez-Ronda, Charlotte Harvey, Mi Ok Chung, Devan Mehrotra, Jeffrey Chodakewitz & 1 others Bach Yen Nguyen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives: To compare the efficacy and safety of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. Design: Two multicenter, open-label, randomized 24-week studies. Methods: Adults HIV-1 infection, HIV-1 RNA greater than 10 000 copies/ml, and no prior lamivudine or protease inhibitor therapy were eligible. In a pilot study (Study A), patients received indinavir at 800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h. In a subsequent study (Study B), patients received indinavir at 800 mg every 8 h or 1200 mg every 12 h. All subjects received zidovudine (300 mg) and lamivudine (150 mg) every 12 h. An intent-to-treat analysis was used. Results: In Study A, which enrolled 88 patients, neither HIV-1 RNA nor CD4 cell responses differed significantly between treatment groups at 24 weeks when corrected for multiple comparisons. Study B enrolled 433 patients, but was prematurely discontinued when interim analysis suggested greater efficacy of three-times-daily indinavir. Of the first 87 patients reaching week 24, HIV-1 RNA was less than 400 copies/ml in 91% receiving three-times-daily versus 64% receiving two-times-daily indinavir (P < 0.01). Conclusion: Three-times-daily indinavir appears more efficacious than two-times-daily dosing when administered with zidovudine and lamivudine. Two-times-daily indinavir dosing should only be considered in situations characterized by favorable pharmacokinetic drug-drug interactions. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)1973-1978
Number of pages6
JournalAIDS
Volume14
Issue number13
DOIs
StatePublished - Sep 8 2000
Externally publishedYes

Fingerprint

Indinavir
Lamivudine
Zidovudine
HIV-1
RNA
Protease Inhibitors
Drug Interactions
HIV Infections
Pharmacokinetics
Safety

Keywords

  • Antiretroviral therapy
  • Clinical trial
  • HIV infection
  • HIV protease inhibitors
  • Indinavir
  • Lamivudine
  • Viral load
  • Zidovudine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Haas, D. W., Arathoon, E., Thompson, M. A., De Jesus Pedro, R., Gallant, J. E., Uip, D. E., ... Nguyen, B. Y. (2000). Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS, 14(13), 1973-1978. https://doi.org/10.1097/00002030-200009080-00013

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. / Haas, David W.; Arathoon, Eduardo; Thompson, Melanie A.; De Jesus Pedro, Rogiero; Gallant, Joel E.; Uip, David E.; Currier, Judith; Noriega, L. Miguel; Lewi, David S.; Uribe, Patricia; Benetucci, Jorge; Cahn, Pedro; Paar, David; White, A. Clinton; Collier, Ann C.; Ramirez-Ronda, Carlos H.; Harvey, Charlotte; Chung, Mi Ok; Mehrotra, Devan; Chodakewitz, Jeffrey; Nguyen, Bach Yen.

In: AIDS, Vol. 14, No. 13, 08.09.2000, p. 1973-1978.

Research output: Contribution to journalArticle

Haas, DW, Arathoon, E, Thompson, MA, De Jesus Pedro, R, Gallant, JE, Uip, DE, Currier, J, Noriega, LM, Lewi, DS, Uribe, P, Benetucci, J, Cahn, P, Paar, D, White, AC, Collier, AC, Ramirez-Ronda, CH, Harvey, C, Chung, MO, Mehrotra, D, Chodakewitz, J & Nguyen, BY 2000, 'Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine', AIDS, vol. 14, no. 13, pp. 1973-1978. https://doi.org/10.1097/00002030-200009080-00013
Haas, David W. ; Arathoon, Eduardo ; Thompson, Melanie A. ; De Jesus Pedro, Rogiero ; Gallant, Joel E. ; Uip, David E. ; Currier, Judith ; Noriega, L. Miguel ; Lewi, David S. ; Uribe, Patricia ; Benetucci, Jorge ; Cahn, Pedro ; Paar, David ; White, A. Clinton ; Collier, Ann C. ; Ramirez-Ronda, Carlos H. ; Harvey, Charlotte ; Chung, Mi Ok ; Mehrotra, Devan ; Chodakewitz, Jeffrey ; Nguyen, Bach Yen. / Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. In: AIDS. 2000 ; Vol. 14, No. 13. pp. 1973-1978.
@article{bc37dac9135142b4b86140f83b1dc387,
title = "Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine",
abstract = "Objectives: To compare the efficacy and safety of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. Design: Two multicenter, open-label, randomized 24-week studies. Methods: Adults HIV-1 infection, HIV-1 RNA greater than 10 000 copies/ml, and no prior lamivudine or protease inhibitor therapy were eligible. In a pilot study (Study A), patients received indinavir at 800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h. In a subsequent study (Study B), patients received indinavir at 800 mg every 8 h or 1200 mg every 12 h. All subjects received zidovudine (300 mg) and lamivudine (150 mg) every 12 h. An intent-to-treat analysis was used. Results: In Study A, which enrolled 88 patients, neither HIV-1 RNA nor CD4 cell responses differed significantly between treatment groups at 24 weeks when corrected for multiple comparisons. Study B enrolled 433 patients, but was prematurely discontinued when interim analysis suggested greater efficacy of three-times-daily indinavir. Of the first 87 patients reaching week 24, HIV-1 RNA was less than 400 copies/ml in 91{\%} receiving three-times-daily versus 64{\%} receiving two-times-daily indinavir (P < 0.01). Conclusion: Three-times-daily indinavir appears more efficacious than two-times-daily dosing when administered with zidovudine and lamivudine. Two-times-daily indinavir dosing should only be considered in situations characterized by favorable pharmacokinetic drug-drug interactions. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Antiretroviral therapy, Clinical trial, HIV infection, HIV protease inhibitors, Indinavir, Lamivudine, Viral load, Zidovudine",
author = "Haas, {David W.} and Eduardo Arathoon and Thompson, {Melanie A.} and {De Jesus Pedro}, Rogiero and Gallant, {Joel E.} and Uip, {David E.} and Judith Currier and Noriega, {L. Miguel} and Lewi, {David S.} and Patricia Uribe and Jorge Benetucci and Pedro Cahn and David Paar and White, {A. Clinton} and Collier, {Ann C.} and Ramirez-Ronda, {Carlos H.} and Charlotte Harvey and Chung, {Mi Ok} and Devan Mehrotra and Jeffrey Chodakewitz and Nguyen, {Bach Yen}",
year = "2000",
month = "9",
day = "8",
doi = "10.1097/00002030-200009080-00013",
language = "English (US)",
volume = "14",
pages = "1973--1978",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine

AU - Haas, David W.

AU - Arathoon, Eduardo

AU - Thompson, Melanie A.

AU - De Jesus Pedro, Rogiero

AU - Gallant, Joel E.

AU - Uip, David E.

AU - Currier, Judith

AU - Noriega, L. Miguel

AU - Lewi, David S.

AU - Uribe, Patricia

AU - Benetucci, Jorge

AU - Cahn, Pedro

AU - Paar, David

AU - White, A. Clinton

AU - Collier, Ann C.

AU - Ramirez-Ronda, Carlos H.

AU - Harvey, Charlotte

AU - Chung, Mi Ok

AU - Mehrotra, Devan

AU - Chodakewitz, Jeffrey

AU - Nguyen, Bach Yen

PY - 2000/9/8

Y1 - 2000/9/8

N2 - Objectives: To compare the efficacy and safety of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. Design: Two multicenter, open-label, randomized 24-week studies. Methods: Adults HIV-1 infection, HIV-1 RNA greater than 10 000 copies/ml, and no prior lamivudine or protease inhibitor therapy were eligible. In a pilot study (Study A), patients received indinavir at 800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h. In a subsequent study (Study B), patients received indinavir at 800 mg every 8 h or 1200 mg every 12 h. All subjects received zidovudine (300 mg) and lamivudine (150 mg) every 12 h. An intent-to-treat analysis was used. Results: In Study A, which enrolled 88 patients, neither HIV-1 RNA nor CD4 cell responses differed significantly between treatment groups at 24 weeks when corrected for multiple comparisons. Study B enrolled 433 patients, but was prematurely discontinued when interim analysis suggested greater efficacy of three-times-daily indinavir. Of the first 87 patients reaching week 24, HIV-1 RNA was less than 400 copies/ml in 91% receiving three-times-daily versus 64% receiving two-times-daily indinavir (P < 0.01). Conclusion: Three-times-daily indinavir appears more efficacious than two-times-daily dosing when administered with zidovudine and lamivudine. Two-times-daily indinavir dosing should only be considered in situations characterized by favorable pharmacokinetic drug-drug interactions. (C) 2000 Lippincott Williams and Wilkins.

AB - Objectives: To compare the efficacy and safety of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. Design: Two multicenter, open-label, randomized 24-week studies. Methods: Adults HIV-1 infection, HIV-1 RNA greater than 10 000 copies/ml, and no prior lamivudine or protease inhibitor therapy were eligible. In a pilot study (Study A), patients received indinavir at 800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h. In a subsequent study (Study B), patients received indinavir at 800 mg every 8 h or 1200 mg every 12 h. All subjects received zidovudine (300 mg) and lamivudine (150 mg) every 12 h. An intent-to-treat analysis was used. Results: In Study A, which enrolled 88 patients, neither HIV-1 RNA nor CD4 cell responses differed significantly between treatment groups at 24 weeks when corrected for multiple comparisons. Study B enrolled 433 patients, but was prematurely discontinued when interim analysis suggested greater efficacy of three-times-daily indinavir. Of the first 87 patients reaching week 24, HIV-1 RNA was less than 400 copies/ml in 91% receiving three-times-daily versus 64% receiving two-times-daily indinavir (P < 0.01). Conclusion: Three-times-daily indinavir appears more efficacious than two-times-daily dosing when administered with zidovudine and lamivudine. Two-times-daily indinavir dosing should only be considered in situations characterized by favorable pharmacokinetic drug-drug interactions. (C) 2000 Lippincott Williams and Wilkins.

KW - Antiretroviral therapy

KW - Clinical trial

KW - HIV infection

KW - HIV protease inhibitors

KW - Indinavir

KW - Lamivudine

KW - Viral load

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0034622987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034622987&partnerID=8YFLogxK

U2 - 10.1097/00002030-200009080-00013

DO - 10.1097/00002030-200009080-00013

M3 - Article

VL - 14

SP - 1973

EP - 1978

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -